Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental Two-Pronged immune therapy tackles tough lymphoma

NCT ID NCT05149391

Completed Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new cell therapy called C-CAR039 in 3 adults with B-cell non-Hodgkin's lymphoma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target two proteins (CD19 and CD20) on cancer cells. The main goal was to check safety and find the right dose, with early signs of effectiveness also tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
C-CAR039 (a type of immune cell therapy that targets two proteins on cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell lymphoma.
What could go wrong
This is a very early phase 1 trial with only 3 participants, so results may not apply broadly. Side effects from CAR T-cell therapy can be severe, including cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement mantle cell lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN'S LYMPHOMA

Contacts and locations

Locations

  • Peking University Cancer Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.